NIKI on Nasdaq

Niki BioSolutions, Inc.

Measuring and controlling devices company in the Cayman Islands. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

-$1.4MNet income, fiscal 2025²

Compare with Quantum-Si Inc, AUTOSCOPE TECHNOLOGIES CORP or Birchtech Corp., or pick any stock.

TickerNIKI on Nasdaq¹
IndustryMeasuring & Controlling Devices, NEC¹
HeadquartersPrinceton, New Jersey¹
Incorporated inCayman Islands³
Business address116 Village Boulevard, Suite 200, Princeton, Nj 08540³
Filer categoryNon-accelerated filer, Smaller reporting company³

See how the biggest companies compare on our leaderboards

October 13, 2017, ordinary resolutions were passed at an extraordinary general meeting of the Company approving (the “Conversions”):⁴ From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-654.8%Net margin²

-66.7%Revenue growth, 2023²

-11.4%Return on equity⁵

-$7.7MFree cash flow²

Where the money goes

Where each dollar of revenue went, fiscal 2023

Research and development

Cost of revenue7¢$420.8K
Research and development93¢$5.2M

Out of $431.4K in revenue.² The company lost money this year.

Financial statements

Revenue⁶⁵²$431.4K in 2023−72% since 2021

Net income⁷⁸⁹⁶⁵²-$2.8M in 2023−81% since 2018

Every line of the income statement as filed: the last 3 fiscal years, latest first.²

Period ending	2025-12-31	2024-12-31	2023-12-31
Healthcare services income			$431.4K
Cost of healthcare services			-$420.8K
Research and development expenses	-$352.9K	-$2.2M	-$5.2M
General and administrative fees	-$573.1K	-$669.5K	-$1.9M
Legal and professional fees	-$1.1M	-$803.3K	-$2.5M
Other operating income (expenses)	$170.8K	-$272.6K	-$1.1M
Total operating expenses	-$1.8M	-$3.9M	-$11.2M
Loss on investments in marketable securities, net			-$9.3K
Unrealized gain from fair value change of the long-term investments, net			$6.4M
Impairment loss of long-term investment		-$1.0M	-$77.2K
Interest expense, net	-$95.7K	-$146.9K	-$121.1K
Gain on disposal of subsidiaries		$703
Issuance cost allocated to warrant liability	-$153.2K
Change in fair value of warrant liability	$690.0K
Government subsidies		$928.5K	$123.0K
Sundry income		$564	$36.8K
Total other income (expense), net	$441.1K	-$217.2K	$6.4M
Net loss	-$1.4M	-$4.2M	-$4.3M
Net income (loss) attributable to non-controlling interests	$13.2K	-$110.1K	$1.5M
Net loss attributable to Aptorum Group Limited	-$1.4M	-$4.3M	-$2.8M
Basic (in Dollars per share)	-$0.19	-$0.78	-$0.62
Diluted (in Dollars per share)	-$0.19	-$0.78	-$0.62
Basic (in Shares)	7.4M shares	5.5M shares	4.5M shares
Diluted (in Shares)	7.4M shares	5.5M shares	4.5M shares
Exchange differences on translation of foreign operations	-$181.5K	$99.8K	-$44.4K
Other comprehensive (loss) income	-$181.5K	$99.8K	-$44.4K
Comprehensive loss	-$1.6M	-$4.1M	-$4.4M
Comprehensive (loss) income attributable to non-controlling interests	-$13.2K	$110.1K	-$1.5M
Comprehensive loss attributable to the shareholders of Aptorum Group Limited	-$1.5M	-$4.2M	-$2.9M

Total assets¹⁰⁷⁸⁹⁶⁵$20.6M in 2023−54% since 2018

Total liabilities¹⁰⁷⁸⁹⁶⁵$5.3M in 2023−57% since 2018

Shareholders’ equity¹⁰⁷⁸⁹⁶⁵$24.8M in 2023−25% since 2018

Cash¹⁰⁶⁵²$2.0M in 2023−83% since 2018

Long-term debt¹⁰⁷⁸⁹$129.8K in 2022−96% since 2018

Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 5 quarters (quarterly), latest first.²

Period ending	2025-12-31	2024-12-31	2023-12-31	2023-01-31	2022-12-31
Cash and cash equivalents	$3.5M	$874.2K
Other receivables and prepayments	$139.6K	$85.3K
Total current assets	$3.6M	$959.6K
Long-term investments, net	$15.1M	$15.1M
Long-term deposits		$71.8K
Total Assets	$18.7M	$16.1M
Accounts payable and accrued expenses	$1.1M	$918.6K
Operating lease liabilities, current	$24.4K	$102.2K
Total current liabilities	$4.6M	$4.3M
Operating lease liabilities, non-current		$14.2K
Warrant liability	$306.0K
Total Liabilities	$4.9M	$4.4M
Contingently redeemable warrants	$47.0K
Total temporary equity	$47.0K
Additional paid-in capital	$97.0M	$93.5M
Accumulated other comprehensive (loss) income	-$92.3K	$89.2K
Accumulated deficit	-$73.8M	-$72.4M
Total equity attributable to the shareholders of Aptorum Group Limited	$23.1M	$21.1M
Non-controlling interests	-$9.4M	-$9.4M
Total equity	$13.7M	$11.8M	$15.4M		$7.8M
Total Liabilities, Temporary Equity and Equity	$18.7M	$16.1M
Ordinary shares, par value (in Dollars per share)				$1.00

Period ending	2025-12-31	2024-12-31	2023-12-31	2023-01-31	2022-12-31
Cash and cash equivalents	$3.5M	$874.2K
Other receivables and prepayments	$139.6K	$85.3K
Total current assets	$3.6M	$959.6K
Long-term investments, net	$15.1M	$15.1M
Long-term deposits		$71.8K
Total Assets	$18.7M	$16.1M
Accounts payable and accrued expenses	$1.1M	$918.6K
Operating lease liabilities, current	$24.4K	$102.2K
Total current liabilities	$4.6M	$4.3M
Operating lease liabilities, non-current		$14.2K
Warrant liability	$306.0K
Total Liabilities	$4.9M	$4.4M
Contingently redeemable warrants	$47.0K
Total temporary equity	$47.0K
Additional paid-in capital	$97.0M	$93.5M
Accumulated other comprehensive (loss) income	-$92.3K	$89.2K
Accumulated deficit	-$73.8M	-$72.4M
Total equity attributable to the shareholders of Aptorum Group Limited	$23.1M	$21.1M
Non-controlling interests	-$9.4M	-$9.4M
Total equity	$13.7M	$11.8M	$15.4M		$7.8M
Total Liabilities, Temporary Equity and Equity	$18.7M	$16.1M
Ordinary shares, par value (in Dollars per share)				$1.00

Cash from operations⁷⁸⁹⁶⁵²-$7.7M in 2023−23% since 2018

Capital spending⁷⁸⁹⁶⁵²$3.0K in 2023−100% since 2018

Free cash flow⁷⁸⁹⁶⁵²-$7.7M in 2023−51% since 2018

Every line of the cash flow as filed: the last 3 fiscal years, latest first.²

Period ending	2025-12-31	2024-12-31	2023-12-31
Net loss	-$1.4M	-$4.2M	-$4.3M
Amortization and depreciation		$255.0K	$1.1M
Issuance cost in relation to warrant	$153.2K
Change in fair value of warrant liability	-$690.0K
Share-based compensation			$1.3M
Loss on investments in marketable securities, net			$9.3K
Unrealized loss (gain) from fair value change of the long-term investments, net			-$6.4M
Impairment loss of long-term investment		$1.0M	$77.2K
(Gain) loss on disposal of long-lived assets		-$58.6K	$110.9K
Impairment loss on long-lived assets		$1.7M	$750.4K
Allowance for credit loss of due from a related party			$521.0K
Write-off of prepayment and other receivables		$45.7K	$62.4K
Write-off of accounts receivable		$6.3K
Write-down of inventories			$13.2K
Gain on disposal of subsidiaries		-$703
Amortization of right-of-use assets		$50.5K	$252.3K
Interest expense and accretion of convertible debts	$180.0K	$180.0K	$45.3K
Reversal of deferred cash bonus			-$1.6M
Accounts receivable		$41.3K	$126.7K
Inventories			$14.5K
Other receivables and prepayments	$17.5K	$291.1K	$227.5K
Long-term deposits			$29.1K
Amounts due from related parties		$961	$63.0K
Amounts due to related parties	-$464	$464	-$8.5K
Accounts payable and accrued expenses	-$28.4K	-$422.7K	$398.6K
Operating lease liabilities	-$92.0K	-$120.8K	-$389.4K
Net cash used in operating activities	-$1.8M	-$1.2M	-$7.7M
Purchases of property and equipment			-$3.0K
Proceeds from disposal of property and equipment		$58.6K	$15.4K
Proceeds from sales of investment securities			$93.2K
Loan to a related party			-$92.5K
Repayment of loan and interest from a related party			$611.6K
Net cash provided by investing activities		$58.6K	$624.8K
Loan from related parties			$2.5M
Proceeds from issuance of Class A Ordinary Shares and warrant	$2.0M		$1.6M
Exercise of share options			$16.5K
Payments related to offering costs	-$284.0K
Repayment of bank loan			-$3.0M
Proceeds from issuance of convertible notes			$3.0M
Proceeds from issuance of Class A Ordinary Shares	$3.1M
Payments related to offering costs	-$370.8K
Net cash provided by financing activities	$4.4M		$4.1M
Net increase (decrease) in cash and cash equivalents and restricted cash	$2.6M	-$1.1M	-$3.0M
Interest paid			$94.1K
Reclassification of placement agent warrant redemption amount	$47.0K
Right-of-use assets obtained in exchange for new operating lease liabilities			$338.5K
Convertible notes converted to Class A Ordinary Shares			$6.0M
Settlement of deferred cash bonus by issuance of share options		$451.7K	$3.1M

Compare Niki BioSolutions, Inc. with another company

Leadership

Who has led Niki BioSolutions, Inc., and when. Pick a name to see everywhere that person has worked.

President

Alidad Mireskandari2026–now

Chief operating officer

Alidad Mireskandari2026–now

PresidentAlidad Mireskandari Jul 28, 2026 to now¹¹
Chief operating officerAlidad Mireskandari Jul 28, 2026 to now¹¹

Board members and other officers (4)

Board memberKira Sheinerman Jul 24, 2026 to now¹²
Board memberLaura A. Philips Jul 24, 2026 to now¹³
Board memberDouglas Wayne Arner Aug 13, 2026 to now¹⁴
Board memberJustin Che Yuen Wu Aug 13, 2026 to now¹⁵

Former names

Aptorum Group LtdMar 28, 2018 to Jun 22, 2026³

Filings

133 filings to the SEC since October 2021: 6 annual reports, 8 major events, 5 insider forms, 8 large holders, 106 other. The latest 20:

Oct 13, 20268-K CURRENT REPORT EDGAR
Oct 9, 2026EFFECT EDGAR
Oct 9, 20268-K CURRENT REPORT EDGAR
Oct 9, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR
Oct 2, 2026S-3/A PRE-EFFECTIVE AMENDMENT NO. 3 TO FORM S-3 EDGAR
Sep 18, 2026S-3/A PRE-EFFECTIVE AMENDMENT 2 TO FORM S-3 EDGAR
Sep 14, 20268-K CURRENT REPORT EDGAR
Sep 4, 20268-K CURRENT REPORT EDGAR
Aug 28, 2026RW WITHDRAWAL REQUEST EDGAR
Aug 28, 2026S-3 REGISTRATION STATEMENT EDGAR
Aug 21, 20268-K/A AMENDMENT NO. 1 TO FORM 8-K EDGAR
Aug 21, 20268-K CURRENT REPORT EDGAR
Aug 13, 20263 EDGAR
Aug 13, 20263 EDGAR
Aug 7, 20268-K CURRENT REPORT EDGAR
Jul 28, 20263 EDGAR
Jul 24, 2026SCHEDULE 13D EDGAR
Jul 24, 20263 EDGAR
Jul 24, 20263 EDGAR
Jul 20, 20268-K CURRENT REPORT EDGAR

The 133 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Kira SheinermanSCHEDULE 13D, 1 filing Jul 24, 2026¹⁶
L1 Capital Global Opportunities Master Fund, Ltd.SCHEDULE 13G/A, 2 filings Jan 6, 2025 to May 15, 2025¹⁷
SCOGGIN MANAGEMENT LPSCHEDULE 13G, 1 filing Jan 10, 2025¹⁸
Darren LuiSC 13D/A, 2 filings May 24, 2023 to Apr 16, 2024¹⁹
Hudson Bay Capital Management LPSC 13G/A, 2 filings Feb 7, 2022 to Feb 2, 2024²⁰

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARNiki BioSolutions, Inc. filings on SEC EDGAR
2
SEC EDGARNiki BioSolutions, Inc. 10-K for fiscal 2025
3
SEC EDGARNiki BioSolutions, Inc. filings on SEC EDGAR
4
SEC EDGARNiki BioSolutions, Inc. annual report, Item 1 (Business)
5
SEC EDGARNiki BioSolutions, Inc. 10-K for fiscal 2023
6
SEC EDGARNiki BioSolutions, Inc. 10-K for fiscal 2021
7
SEC EDGARNiki BioSolutions, Inc. 10-K for fiscal 2018
8
SEC EDGARNiki BioSolutions, Inc. 10-K for fiscal 2019
9
SEC EDGARNiki BioSolutions, Inc. 10-K for fiscal 2020
10
SEC EDGARNiki BioSolutions, Inc. 10-K for fiscal 2018
11
SEC EDGARAlidad Mireskandari, President
12
SEC EDGARKira Sheinerman, Board member
13
SEC EDGARLaura A. Philips, Board member
14
SEC EDGARDouglas Wayne Arner, Board member
15
SEC EDGARJustin Che Yuen Wu, Board member
16
SEC EDGARKira Sheinerman SCHEDULE 13D on Niki BioSolutions, Inc.
17
SEC EDGARL1 Capital Global Opportunities Master Fund, Ltd. SCHEDULE 13G/A on Niki BioSolutions, Inc.
18
SEC EDGARSCOGGIN MANAGEMENT LP SCHEDULE 13G on Niki BioSolutions, Inc.
19
SEC EDGARDarren Lui SC 13D/A on Niki BioSolutions, Inc.
20
SEC EDGARHudson Bay Capital Management LP SC 13G/A on Niki BioSolutions, Inc.